Alimera Sciences Foglalás / Részvény
Mi az Alimera Sciences Foglalás / Részvény?
A Foglalás / Részvény az Alimera Sciences Inc. - 15.17
Mi a Foglalás / Részvény meghatározása?
Az egy részvényre jutó könyv szerinti érték egy vállalat eszköze, mínusz kötelezettségek, osztva a fennálló részvények számával.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Foglalás / Részvény a Health Care szektor a NASDAQ-on cégekben a Alimera Sciences -hoz képest
Mit csinál Alimera Sciences?
alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
foglalás / részvény -hoz hasonló cégek Alimera Sciences
- BJ`s Restaurant nak Foglalás / Részvény 15.14 van
- Nikon nak Foglalás / Részvény 15.14 van
- Nuveen S&P 500 Buy-Write Income Fund nak Foglalás / Részvény 15.15 van
- Sprott nak Foglalás / Részvény 15.16 van
- Gromo Trade & Consultancy nak Foglalás / Részvény 15.17 van
- Old Point nak Foglalás / Részvény 15.17 van
- Alimera Sciences nak Foglalás / Részvény 15.17 van
- Nuveen New Jersey Quality Municipal Income Fund nak Foglalás / Részvény 15.18 van
- Eaton Vance Senior Floating-Rate Trust nak Foglalás / Részvény 15.19 van
- H. Lundbeck A/S nak Foglalás / Részvény 15.19 van
- COSCO SHIPPING Co nak Foglalás / Részvény 15.19 van
- ReNeuron plc nak Foglalás / Részvény 15.19 van
- Tristate nak Foglalás / Részvény 15.19 van